epoetin alfa human erythropoietin produced cell culture using recombinant dna authorised european medicines agency august stimulates erythropoiesis increasing red blood cell levels used treat anemia commonly associated chronic kidney failure cancer chemotherapy epoetin manufactured marketed amgen brand name epogen johnson johnson subsidiary janssen biotech formerly ortho biotech products lp sells drug name procrit pursuant product license agreement average cost per patient us darbepoetin alfa rinn dɑːrbəˈpɔɪtɪn glycosylation analog erythropoietin containing two additional nlinked carbohydrate also manufactured marketed amgen brand name aranesp food drug administration fda warnings safety precautions procrit epogen aranesp identical several years epoetin alfa accounted single greatest drug expenditure paid us medicare system program paid billion raising hemoglobin levels found studies associated higher risks thrombotic events strokes world health organizations list essential erythropoietin available therapeutic agent produced recombinant dna technology mammalian cell culture used treating anemia resulting chronic kidney disease myelodysplasia treatment cancer chemotherapy radiationcitation needed people require dialysis chronic kidney disease iron given erythropoietin depending laboratory parameters ferritin transferrin dialysis patients us often given epogen brands epoetin may used countriescitation needed erythropoietin also used treat anemia people cats dogs chronic kidney disease dialysis stage disease living kidney transplant two types erythropoietin people cats dogs anemia due chronic kidney disease march panel advisers us food drug administration fda supported keeping erythropoiesisstimulating agents esas produced amgen johnson johnson market use cancer patients fda focused concern study results clinical trials showing increased risk death tumor growth chemotherapy patients taking antianemia drugscitation needed erythropoietin used treat people anemia resulting critical illness randomized controlled erythropoietin shown change number blood transfusions required critically ill patients surprising finding study small mortality reduction patients receiving erythropoietin result statistically significant days days mortality difference marked patients admitted icu trauma authors provide several hypotheses potential etiologies reduced mortality given known increase thrombosis increased benefit trauma patients well marginal nonsignificant benefit adjusted hazard ratio surgery patients could speculated benefit might secondary procoagulant effect erythropoietin regardless study suggests research may necessary see critical care patients might benefit administration erythropoietin benefit erythropoietin use must weighed increased likelihood thrombosis demonstrated numerous trialscitation needed erythropoietin hypothesized beneficial treating certain neurological diseases schizophrenia research suggested erythropoietin improves survival rate children cerebral malaria caused malaria parasites blockage blood vessels however possibility erythropoietin may neuroprotective inconsistent poor transport chemical low levels erythropoietin receptors expressed neuronal cells psychiatric diseases randomized clinical control trials shown promising results epo improving cognition often intractable current treatment mood disorders schizophreniathese domains include speed complex cognitive processing across attentionmemory executive infants born early often require transfusions red blood cells low levels erythropoietin erythropoietin studied treatment option reduce anemia preterm infants treating infants less days old erythropoietin may slightly reduce need red blood cell transfusions increases risk retinopathy due limited clinical benefit increased risk retinopathy early late erythropoietin treatment recommended preterm epoetin alfa generally well tolerated common side effects include high blood pressure headache disabling cluster migraine resistant remedies joint pain clotting injection site rare cases stinging injection site skin rash flulike symptoms joint muscle pain occurred within hours following administration serious side effects including allergic reactions seizures thrombotic events eg heart attacks strokes pulmonary embolism rarely occur chronic selfadministration drug shown cause increases blood hemoglobin hematocrit abnormally high levels resulting dyspnea abdominal erythropoietin associated increased risk adverse cardiovascular complications patients kidney disease used target increase hemoglobin levels early treatment infant days old erythropoietin correlated increase risk retinopathy prematurity premature anemic infants raising concern angiogenic actions erythropoietin may exacerbate since anemia increases risk retinopathy correlation erythropoietin treatment may incidentalcitation needed amgen sent dear doctor letter january highlighted results recent anemia cancer trial warned doctors consider use offlabel indication cautioncitation needed amgen advised us food drug administration fda regarding results dahanca clinical trial dahanca data monitoring committee found threeyear locoregional cancer control subjects treated aranesp significantly worse receiving aranesp needed response advisories fda released public health march clinical doctors february use erythropoiesisstimulating agents esas epogen darbepoetin advisory recommended caution using agents cancer patients receiving chemotherapy chemotherapy indicated lack clinical evidence support improvements quality life transfusion requirements settings addition march drug manufacturers agreed new black box warnings safety drugs march congressional inquiry safety erythropoietic growth factors reported news media manufacturers asked suspend drug rebate programs physicians also suspend marketing drugs patients several publications fda communications increased level concern related adverse effects esa therapy selected groups revised black box warning fda notes significant risks advising esas used patients cancer treating anemia specifically caused chemotherapy causes anemia warning states esas discontinued patients chemotherapy course drug interactions erythropoietin include publication editorial questioning benefits highdose epoetin canceled marketing branch journal accepted editorial branch highlighting concerns conflict interest author kathleen sharp published book blood feud man blew whistle one deadliest prescription drugs alleging drug maker johnson johnson encouraged doctors prescribe epoetin high doses particularly cancer patients would increase sales hundreds millions dollars former sales representatives mark duxbury dean mcclennan claimed bulk business selling epoetin hospitals clinics medicare fraud totaling august binocrit epoetin alfa hexal abseamed approved use european httpsenwikipediaorgwikiepoetinalfa